APAdem Parlak

Adem Parlak

*This is an algorithmically generated author record based on publicly available information.

Adem Parlak has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The effect of levothyroxine replacement therapy on lipid profile and oxidative stress parameters in patients with subclinical hypothyroid

    by Serkan Mutlu, Adem Parlak, Umit Aydogan, Aydogan Aydogdu, Bugra Soykut, Cemal Akay, Kenan Saglam, Abdullah Taslipinar

    The purpose of this present study is to investigate the levels of oxidative stress parameters in patients with subclinical hypothyroidism (SH) and the effects of levothyroxine (LT4) replacement therapy on these parameters and lipid profile. At the beginning of the study blood samples were collected from the patients in order to analyse oxidative stress parameters, lipid profile and biochemical markers. After replacement therapy with LT4, in the third month, same tests were performed again. At the baseline superoxide dismutase (SOD) levels were found to be higher in SH patients, compared to the euthyroid group. After LT4 therapy, statistically significant decreases in SOD and catalase levels and increase in HDL-C levels were noticed. LT4 treatment was found to have positive effects on oxidative stress indicators and HDL-C levels.


  • The effects of valsartan treatment on visfatin levels and lipid profiles in newly diagnosed hypertensives

    by İsmai̇l Atacan, Adem Parlak, Ümi̇t Aydoğan, Oktay Sari, Deni̇z Engi̇n Gök, Tuncer Çayci, Kenan Sağlam

    In this study, the curative effect of valsartan on hypertension based on its effect on visfatin levels and lipid profiles was investigated. Materials and methods: Forty patients aged 38-60 with hypertension were included in the study. In order to determine initial visfatin levels and lipid profiles, blood samples were taken from the patients and all were started on 80-mg valsartan tablets. All patients were monitored for 12 weeks. Results: By using multivariate regression analysis, it was determined that visfatin levels affected systolic blood pressure (SBP) (P = 0.012, beta; -0.43, 95% CI: -0.092 to -0.012). After the patients received the valsartan treatment for 12 weeks, a significant increase in visfatin levels was observed (pre- and posttreatment, respectively: 0.42 ± 0.22 ng/mL and 0.71 ± 0.36 ng/mL, P < 0.001). When the lipid profile changes of patients were examined, only low-density lipoprotein (LDL) levels showed a statistically significant change (pre- and posttreatment, respectively: 150.32 ± 13.22 mg/dL and 143.82 ± 7.53 mg/dL, P = 0.008). Conclusion: In this study, it was found that visfatin levels affected SBP in newly diagnosed hypertensive patients and valsartan treatment increased visfatin levels. In addition, the use of valsartan reduced LDL levels.


  • The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients

    by Adem Parlak, Atila Iyisoy, Umit Aydogan, Erdinc Cakir, Kenan Saglam


  • Open Access

    Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: an observational study

    by Adem Parlak, Umit Aydogan, Atila Iyisoy, Mehmet Aytug Dikililer, Altug Kut, Erdinc Cakir, Kenan Saglam

    In this study, relationship between systolic and diastolic blood pressure and pentraxin-3 (PTX3) levels in hypertensive patients was investigated. Overall, 80 patients with stage 1 hypertension between 40-61 years of age without any disease and 80 healthy volunteers were included to the study. Blood samples obtained to measure PTX3 levels and biochemical analysis. Relationship between PTX3 levels and clinical and biochemical parameters were analyzed using multivariate regression analysis. Although systolic and diastolic blood pressures were significant different, there were no differences regarding age and gender between hypertensives and normotensives. In each group, significant statistical differences were found between PTX3 and CRP levels (PTX3 (ng/mL) 35.25±5.45 and 0.27±0.24, p0.05). On multivariate regression analysis PTX3 was found to strongly affect blood pressure (beta=0.82, 95% CI 0.644-0.799, p<0.001, and beta=0.84, 95% CI 0.422-0.799, p<0.001, respectively for systolic and diastolic blood pressures), CRP and total cholesterol are found to affect moderately (beta=0.115-0.265, 95% CI 0.101-0.572, p<0.05 and beta=0.107-0.141, 95% CI 0.041-0.110, p<0.05, respectively). This study showed that PTX3 levels are higher in newly diagnosed hypertensive patients than in healthy individuals. In addition, it was noticed that increased PTX3 levels causes increase in systolic and diastolic blood pressures.